Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care PMA Filed
This article was originally published in The Gray Sheet
Executive Summary
Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy
You may also be interested in...
Financings In Brief
Device VC activity increases
Financings In Brief
Device VC activity increases
GIFT Study: Genetic Testing Viable For Personalizing Antiplatelet Therapy
A recent study supports a role for genetic testing as a means of personalizing antiplatelet therapy following stent placement and builds the case that newer drugs, such as Eli Lilly/Daiichi Sankyo's Effient (prasugrel), are more appropriate options for those who have poor response to standard Plavix (clopidogrel) treatment.